ECDG
ECDG is a small-molecule compound dependent on α-ketoglutarate/Fe2+ that participates in the biosynthesis of echinocandins. ECDG is involved in the targeted transport of glucose, and can be used for PET imaging after labeling with radioactive atoms. ECDG increases blood glucose levels in rats, undergoes cellular uptake mediated by D-glucose, localizes in ischemic viable myocardial tissue, and accumulates in the synovial space of rheumatoid arthritis. ECDG can be used in research related to candidiasis, glucose metabolism disorders, fungal infections, myocardial ischemia and rheumatoid arthritis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 378230-75-2
- Formule: C20H38N4O12S2
- Masse moléculaire:590.67
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
In Vitro
ECDG (1.0 mg/mL; 3 minutes) undergoes hexokinase-catalyzed phosphorylation, as demonstrated by a positive signal at 341.5 nm in the cell-free hexokinase assay[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Fischer 344 (female, 145-155 g, healthy; female, 250-275 g, inoculated subcutaneously with 13762 mammary tumor cells)[2]
-
Dosage:1.2 mM/kg
-
Administration:i.v. (ECDG, 99mTc ECDG, unlabeled FDG); i.m. (insulin); single dose
-
Result:Increased blood glucose levels in healthy rats, which dropped to ~20 mg/dL by 180 minutes post-insulin injection.
Recorded mean tumor-to-nontumor ROI ratios of 1.70 (immediate), 1.58 (30 minutes), and 1.82 (2 hours) for 3 mm tumors, and 2.36 (immediate), 2.41 (30 minutes), and 2.88 (2 hours) for 6 mm tumors.
Reduced tumor uptake of 99mTc ECDG by 40% following unlabeled FDG pretreatment.
Increased tumor uptake of 99mTc ECDG by 60% following insulin pretreatment.
Enabled better breast tumor visualization than 99mTc ethylenedicysteine at equivalent time points.
Chemical Information
-
CAS No. 378230-75-2
-
Masse moléculaire 590.67
-
Formule C20H38N4O12S2
-
SMILES
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC([C@H](CS)NCCN[C@@H](CS)C(N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO)=O)=O
-
Synonyms
Ethylenedicysteine deoxyglucose
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
Pureté et documentation
Références
[1]. Jiang W, et al. EcdGHK are three tailoring iron oxygenases for amino acid building blocks of the echinocandin scaffold. Journal of the American Chemical Society. 2013 Mar 20;135(11):4457-66. [Content Brief]
[2]. Yang DJ, et al. Imaging with 99mTc ECDG targeted at the multifunctional glucose transport system: feasibility study with rodents. Radiology. 2003 Feb;226(2):465-73. [Content Brief]
[3]. Liu W, et al. Structural Characterization of the l-Homo-Tyrosine β-Hydroxylase EcdG Involved in Echinocandin Biosynthesis Guides the Engineering of Its Homologous Protein GloM. Journal of natural products. 2026 Jun 17. [Content Brief]
[5]. Evbuomwan O, et al. The Biodistribution and Utility of Tc-Ethylenedicysteine-Deoxyglucose (Tc-Glucosamine) in the Identification of Active Disease in Patients with Rheumatoid Arthritis-a Single Center Prospective Study. Nuclear medicine and molecular imaging. 2024 Apr;58(2):52-61. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ECDG Related Classifications
HY-184103 Related Classifications
Powered by Bioz